Pharma's Market
SPECIAL REPORT
- New York Fashion Week Hits the Runway as Colors Pop
- Mulling Buffett's Stock Advice? Get in With REITs: Fund Managers
- LinkedIn Earnings Bode Well for Hiring and Social Media
- Top Five Mistakes to Avoid in Online Dating
- Victor Cruz ‘Understands’ Gisele's Super Bowl Frustrations
- Tamminen: The United States of India
- Unusual Volume: Taleo Jumps After Oracle's $1.9 Billion Offer
- Warren Buffett: Stocks Will Outperform Gold and Bonds .. and They're Safer 'By Far'
- So Now You Can’t Give Microsoft Away?
- Stocks Looking Past Europe for a New Driver of the Rally
- Israel Likely to Bomb Iran This Year: Political Analyst
- Greeks Strike Against Austerity, EU Demands More Cuts
- EU Agrees Rules for $700 Trillion Derivatives Market
- Citigroup Takes $50 Million Loss in Lending Rate Probe
- Barclays Warns May Miss Medium-Term Profit Goal
- Will Romney Regret Opposing Michigan Auto Bailout?
- In Europe, Stagnation as a Way of Life
- The Secret Lives of Traders—Seeking the Next Hot Thing
RSS FEED
Dendreon's Secret "Lover"--With A Strong Ticker
Text Size 
Reporter
 |
] put out a press release this morning announcing that an unidentified institutional investor is going to buy eight million shares and warrants to buy as much as another eight million for a total infusion of $47 million. DNDN says it will use the money to "fund our commercialization activities for Provenge," among other things. Provenge is a therapeutic vaccine for prostate cancer that is in the middle of a crucial clinical trial.
Back in February I blogged about Morgan Stanley and a hedge fund, Visium Asset Management, taking a combined 16.5 percent stake in DNDN. Big investors like that have 45 days to disclose their positions to the Securities and Exchange Commission, so the identity of Dendreon's secret lover could be revealed in the not-too-distant future.
Dendreon can be a very volatile stock. It has a huge short interest or shares that belong to investors who are hoping the price will fall. This is not an investment for the faint of heart. But obviously another one of the "big boys" has a strong ticker.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
